Zymeworks (NASDAQ:ZYME) Stock Gets Price Target Increase from Citizens Jmp

Zymeworks (NASDAQ:ZYME) had its price target hoisted by stock analysts at Citizens Jmp from $32.00 to $39.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp‘s target price would indicate a potential upside of 47.34% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Wolfe Research initiated coverage on shares of Zymeworks in a research note on Thursday, September 17th. They set an “outperform” rating for the company. Deutsche Bank set a $32.00 target price on shares of Zymeworks in a research note on Wednesday, August 26th. HC Wainwright lifted their price target on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday. Stifel Nicolaus set a $46.00 price target on Zymeworks in a research report on Friday, August 7th. Finally, B. Riley Financial reiterated a “buy” rating and set a $44.00 price objective (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zymeworks currently has an average rating of “Moderate Buy” and an average price target of $43.25.

Zymeworks Stock Performance

Shares of Zymeworks stock opened at $26.47 on Friday. The company has a market capitalization of $1.83 billion, a PE ratio of 50.90 and a beta of 1.32. The company has a 50-day simple moving average of $27.39 and a two-hundred day simple moving average of $25.46. Zymeworks has a one year low of $18.20 and a one year high of $31.97.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. During the same period last year, the business earned ($0.26) EPS. The company’s revenue was up 828.7% compared to the same quarter last year. On average, equities analysts predict that Zymeworks will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the sale, the executive vice president owned 23,205 shares in the company, valued at approximately $599,849.25. The trade was a 37.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.

Institutional Trading of Zymeworks

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Zymeworks during the 2nd quarter worth approximately $111,122,000. Rubric Capital Management LP raised its holdings in shares of Zymeworks by 21.7% in the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $175,280,000 after buying an additional 1,250,000 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Zymeworks by 759.9% in the third quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock worth $16,122,000 after buying an additional 537,837 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Zymeworks by 72.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,252,027 shares of the company’s stock worth $32,728,000 after buying an additional 524,041 shares during the last quarter. Finally, Deutsche Bank AG acquired a new stake in shares of Zymeworks during the second quarter worth $10,383,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks News Summary

Investors following ZYME have been watching these news items:

• Positive Sentiment: Zymeworks’ earnings exceeded expectations, and its shares reached a 52-week high following the results. The company reported EPS of $2.28 versus a $2.27 consensus estimate, while revenue also topped forecasts. Zymeworks Hits New 52-Week High After Better-Than-Expected Earnings
• Positive Sentiment: Analysts at TD Cowen raised their price target, while Truist’s forecast pointed to potential price appreciation. Citi also raised its target to $44 and maintained a Buy rating. Zymeworks Stock Gets Price Target Boost from TD Cowen Truist Financial Forecasts Strong Price Appreciation for Zymeworks Citi Raises Zymeworks Price Target
• Negative Sentiment: HC Wainwright substantially reduced its 2026 and 2027 EPS forecasts, including lowering its FY2027 estimate from $1.32 to a loss of $0.39 per share. The cuts to quarterly 2027 estimates may raise concerns about the durability of earnings, although the firm kept its Buy rating and $56 target.

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.